http://www.pressdispensary.co.uk/feed/99552.php

Fu Fang Dan Shen Tablets fight coronary and neurological disease



Press Dispensary - 20 October 2005 - China Business Solutions Ltd
(http://www.ChinaBusinessSolutions.com), a specialist UK service for
companies which plan to carry out business in China, and the
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Ltd,
a manufacturer of approved traditional Chinese medicine (TCM),
announce China's highly respected answer to the treatment of heart
disease: the Fu Fang Dan Shen Tablets.

Representing the modernisation of Chinese medicine, the Fu Fang Dan
Shen Tablets are one of Hutchison Whampoa Guangzhou Baiyunshan's key
products. Effective in the prevention and treatment of coronary
heart disease, the product is the top named brand of its kind in
China and has more than 51% market share.

Containing the herbs radix salviae militorrhizae, radix notoginseng
and borneol, which are produced and regulated through the strict
regulatory requirements of the Good Agricultural Practise (GAP)
production process in China, and prescribed by most Chinese
physicians, the Fu Fang Dan Shen Tablets are highly regarded for
their safety profile and negligible side effects and are approved by
the SFDA - the Chinese equivalent of the Food and Drug
Administration regulatory body (FDA).

As well as treating heart disease, the Fu Fang Dan Shen tablets are
believed to be effective against neurological disorders. Hutchison
Whampoa Guangzhou Baiyunshan is investigating the use of the tablets
for treating senile dementia and Alzheimer's disease. Pre-clinical
study on the application to Alzheimer's has already been completed
and approval for full clinical trials granted in China.

Drawing upon the latest technological tools and techniques, the
Chinese-made Fu Fang Dan Shen Tablets are pressed using the latest
German machines and finished with Canadian coating equipment. They
are subject to rigorous quality control and are manufactured in
accordance with the Standards for Import and Export of Medicinal
Herbs and Preparation of China.

Dr Renan Qin of Hutchison Whampoa Guangzhou Baiyunshan
comments: `Despite popular misconceptions that Chinese medicine is
based on `home made herb cooking with no tangible scientific
procedures' and does not involve clinical trials, in reality it is
vigorous in its formulation, approach and safety profiles. Our Fu
Fang Dan Shen Tablets combine traditional Chinese methods with
modern technology and provide therapeutic treatment for a number of
complaints, especially coronary disease. Our continued investment to
modernise traditional Chinese medicine and develop our own in-house
expertise will eventually mean our products are used throughout the
world for fighting serious diseases.'


Notes for editors
About China Business Solutions
China Business Solutions (CBS) is a Cambridge-based consultancy firm
specialising in business to and from China. It offers a range of
consultancy and research services to help British, European and US
companies enter or expand into the Chinese marketplace and Chinese
companies enter the European market. CBS focuses, in particular, on
technology-related and manufacturing sectors. It is a private,
company with a management team in Cambridge, UK, and strategic
partners in Shanghai, Beijing and Hong Kong.

About Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine
Company Ltd
Baiyunshan (BYS) merged during early 2005 with Hutchison Whampoa.
Hutchison Whampoa Limited (HWL) is an international corporation
operating in the technology sector, with businesses spanning the
globe and a consolidated turnover of USD 23,000 million in 2004. HWL
wanted to invest in BYS's high quality Chinese medical products. The
resulting Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine
Company Limited is a leading light in the modern TCM industry. It
develops TCM-derived therapeutic treatments that combat a range of
diseases. All its products are approved and regulated in the Chinese
marketplace and address clear medical needs. The company's overall
production value is anticipated to reach RMB 1.38 billion (GBP 96.72
million) and its annual sales revenue RMB 1.2 billion (GBP 84.2
million) per year.


For more information, please contact:
Dr Elizabeth Hill Phone: 01223 421 969
Email: eh@...
Site: www.ChinaBusinessSolutions.com

Ting Zhang
CEO and founder of China Business Solutions
Tel: 01223 421 968
http://www.ChinaBusinessSolutions.com